excluded period(s) [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2012-08-16 18:36 (5063 d 23:27 ago) – Posting: # 9073
Views: 12,330

Hi Navoday!

❝ should we submit statistical data with inclusion and exclusion of that subject having predose concentration more than 5% of Cmax or simply delete that subject from all analysis?


Even complying with the guidance I always state the planned procedure in the protocol. I report the PK data (in order to give the assessor a mean to check them) but exclude the subject in a 2×2 cross-over from comparative assessments. If the pre-dose concentration is observed not in all periods and the study is either a replicate or a higher-order cross-over, I proceed as following:

❝ what if study is partial replicate (3WSABE)and that subject has completed TR sequence? as it may help for estimating t1/2 and tmax if average bioequivalence is there.


Since according to the FDA a partial replicate has to be analyzed by SAS Proc GLM (or similar) IMHO all data of the subject will be dropped from the analysis (even if you observe a pre-dose concentration in just one period).

❝ as it may help for estimating t1/2 and tmax if average bioequivalence is there.


Don’t understand what you mean here. :confused:

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
350 visitors (0 registered, 350 guests [including 11 identified bots]).
Forum time: 18:03 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5